CeriBell (NASDAQ:CBLL) Stock Jumps 4.4% - Here's What Happened

CeriBell logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • CeriBell shares rose 4.4% to about $26.89, while trading volume was 33% below the average session volume.
  • Analysts’ consensus rating is “Moderate Buy”, with an average price target of $31.25; TD Cowen raised its target to $33.
  • The latest quarter’s loss per share was wider than expected ($0.55 versus $0.51), though revenue of $29.34 million topped estimates. Company insiders have sold 139,859 shares over the past 90 days.
  • MarketBeat previews top five stocks to own in December.

CeriBell, Inc. (NASDAQ:CBLL - Get Free Report)'s stock price shot up 4.4% during trading on Friday. The company traded as high as $26.76 and last traded at $26.8860. Approximately 249,429 shares traded hands during trading, a decline of 33% from the average session volume of 374,956 shares. The stock had previously closed at $25.75.

Analysts Set New Price Targets

CBLL has been the topic of several analyst reports. BTIG Research reissued a "buy" rating on shares of CeriBell in a research note on Wednesday, November 4th. TD Cowen increased their price objective on CeriBell from $29.00 to $33.00 and gave the company a "buy" rating in a report on Friday, October 2nd. Raymond James Financial reaffirmed a "strong-buy" rating and set a $29.00 target price on shares of CeriBell in a research report on Thursday, September 3rd. Weiss Ratings raised CeriBell from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, October 16th. Finally, Barclays upgraded CeriBell to a "neutral" rating in a research report on Tuesday, August 18th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, CeriBell currently has an average rating of "Moderate Buy" and a consensus price target of $31.25.

Get Our Latest Research Report on CBLL

CeriBell Stock Up 6.2%

The stock has a market cap of $1.06 billion, a price-to-earnings ratio of -13.97 and a beta of 0.86. The company has a current ratio of 8.18, a quick ratio of 7.79 and a debt-to-equity ratio of 0.17. The stock's 50-day moving average price is $25.66 and its 200-day moving average price is $21.15.

CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). CeriBell had a negative return on equity of 52.59% and a negative net margin of 67.96%. The firm had revenue of $29.34 million for the quarter, compared to analyst estimates of $29.18 million. On average, sell-side analysts expect that CeriBell, Inc. will post -2.05 earnings per share for the current year.

Insider Buying and Selling at CeriBell

In related news, CTO Raymond Woo sold 4,887 shares of the company's stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $26.96, for a total transaction of $131,753.52. Following the sale, the chief technology officer owned 203,118 shares in the company, valued at $5,476,061.28. This represents a 2.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Xingjuan Chao sold 20,846 shares of the firm's stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $25.03, for a total value of $521,775.38. Following the sale, the chief executive officer directly owned 746,345 shares of the company's stock, valued at $18,681,015.35. This represents a 2.72% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 139,859 shares of company stock valued at $3,554,775. 17.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On CeriBell

A number of institutional investors and hedge funds have recently modified their holdings of CBLL. BlackRock Inc. bought a new stake in shares of CeriBell in the 2nd quarter valued at $37,657,000. KCM Capital Inc boosted its stake in CeriBell by 40.0% during the first quarter. KCM Capital Inc now owns 1,400,000 shares of the company's stock worth $25,662,000 after acquiring an additional 400,000 shares in the last quarter. Bank of New York Mellon Corp bought a new position in CeriBell during the second quarter worth $17,437,000. TimesSquare Capital Management LLC bought a new position in CeriBell during the second quarter worth $15,182,000. Finally, Goldman Sachs Group Inc. grew its holdings in CeriBell by 25.1% in the third quarter. Goldman Sachs Group Inc. now owns 350,570 shares of the company's stock worth $8,550,000 after purchasing an additional 70,261 shares during the period.

About CeriBell

(Get Free Report)

Ceribell, Inc. develops neurodiagnostic technology for detecting and monitoring seizures. Its products are designed to make electroencephalography (EEG) more accessible in emergency departments and intensive care units, where timely assessment can be important and conventional EEG services may not be readily available. The company's Ceribell point-of-care EEG system combines a headband with electrodes, a portable recorder and software for viewing and analyzing EEG data. Its Clarity algorithm is designed to help clinicians identify patterns associated with seizure activity, while the system supports remote review by specialists.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in CeriBell Right Now?

Before you consider CeriBell, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.

While CeriBell currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines